Omniab, Inc. (OABI) Stock Price & Analysis
Omniab, Inc. (OABI) fell 0.49% to USD 2.03 as of July 26, 2026 at 11:05 UTC, according to Nexqual real-time market data.
OABI last closed at USD 2.04; the session ranged USD 2.03–2.12 on volume of 302,673 shares. Market capitalization is $294.29M, with a 52-week range of USD 1.3–2.79 (NGM). Source: Nexqual, July 26, 2026 at 11:05 UTC.
Key Statistics (as of July 26, 2026 at 11:05 UTC)
| Price | USD 2.03 |
|---|---|
| Change | ▼ 0.49% (down) |
| Previous Close | USD 2.04 |
| Open | USD 2.1 |
| Day Range | USD 2.03 – 2.12 |
| 52-Week Range | USD 1.3 – 2.79 |
| Volume | 302,673 shares |
| Market Cap | $294.29M |
| Exchange | NGM |
Technical Analysis (OABI)
Nexqual's technical model rates OABI "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 11:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.56 (neutral) |
| vs SMA50 | Below (USD 2.33) |
| MACD | -0.07 (negative) |
Analyst Ratings (OABI)
Wall Street analysts rate OABI "None" based on 6 analysts, with a mean price target of USD 7.33 (range USD 3–11), per Nexqual as of July 26, 2026 at 11:05 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 7.33 |
| High Target | USD 11 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (OABI)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.13 |
| Revenue Estimate | $4.69M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.06 vs est -0.1 ▲ beat |
| 2025-12-31 | USD -0.11 vs est -0.09 ▼ miss |
| 2025-09-30 | USD -0.14 vs est -0.14 ▼ miss |
| 2025-06-30 | USD -0.15 vs est -0.15 ▲ beat |
Source: Nexqual, July 26, 2026 at 11:05 UTC.
Financials & Fundamentals (OABI)
| Total Revenue | $28.94M |
|---|---|
| Revenue Growth (YoY) | +247.30% |
| Gross Margin | +98.91% |
| Operating Margin | -54.27% |
| Profit Margin | -187.59% |
| ROE | -20.25% |
| Debt / Equity | 7.49 |
| Current Ratio | 4.8 |
| Total Cash | $49.07M |
| Total Debt | $19.67M |
| Free Cash Flow | $-2.57M |
Source: Nexqual, July 26, 2026 at 11:05 UTC.
Financial Health Score (OABI)
Nexqual rates Omniab, Inc.'s overall financial health "Weak" across five dimensions, as of July 26, 2026 at 11:05 UTC.
| Growth | Critical — Revenue -29% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $49M cash vs $20M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$3M, burning cash |
| Efficiency | Critical — ROE -20%, ROA -11.3% |
Ownership (OABI)
| Insider Ownership | +15.33% |
|---|---|
| Institutional Ownership | +51.01% |
| Shares Outstanding | 144.97M |
| Float | 113.85M |
| Short % of Float | +4.45% |
Source: Nexqual, July 26, 2026 at 11:05 UTC.
Leadership (OABI)
Omniab, Inc. is led by Matthew W. Foehr (age 52), President, CEO & Director, per Nexqual as of July 26, 2026 at 11:05 UTC.
| President, CEO & Director | Matthew W. Foehr (age 52) |
|---|---|
| Executive VP of Finance & CFO | Kurt A. Gustafson (age 57) |
Major Backers & Investors (OABI)
Notable institutional backers of Omniab, Inc. include Whitefort Capital Management, LP, Cadian Capital Management, LP, Rice, Hall, James & Associates LLC, according to Nexqual as of July 26, 2026 at 11:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Whitefort Capital Management, LP | 9.81% |
| Cadian Capital Management, LP | 2.87% |
| Rice, Hall, James & Associates LLC | 1.76% |
| Private Management Group, Inc. | 1.68% |
| Fidelity | 1.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.45% |
| Vanguard Group | 5.8% |
| Geode Capital | 2.02% |
| State Street | 1.43% |
| Dimensional Fund Advisors | 1.2% |
Source: Nexqual, July 26, 2026 at 11:05 UTC.
From Omniab, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- Our partners who use the OmniAb patented technology to generate novel antibodies may be entitled to separate, additional patent protection on such antibodies. 17 Table of Contents Antigen Design Through the Ab Initio acquisition in 2019, we obtained an exclusive license from Stanford University directed to screening methods using transmembrane and cell-surface proteins and related compositions and kits.
- At the heart of the OmniAb platform is what we call Biological Intelligence TM , which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
- We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions.
- Our proprietary transgenic animals, including OmniRat ® , OmniChicken ® and OmniMouse ® have been genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates.
Partnerships
- STR Technology In 2023, OmniAb entered into an agreement with mAbsolve Ltd. for its Fc-silencing platform technology, STR, which is based upon a proprietary engineered human Fc domain.
- Although our license agreements with pharmaceutical and biotechnology partners typically include technology access fees, milestone payments and royalties, each agreement is negotiated separately and as a result, the financial terms and contractual provisions vary from agreement to agreement.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OBIO | Orchestra BioMed Holdings, Inc. | USD 3.74 | ▲ 3.03% |
| DSGN | Design Therapeutics, Inc. | USD 11.78 | ▲ 0% |
| LRMR | Larimar Therapeutics, Inc. | USD 4 | ▼ 0.5% |
| TRDA | Entrada Therapeutics, Inc. | USD 5.85 | ▼ 4.88% |
| PEPG | PepGen Inc. | USD 1.93 | ▲ 0.52% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 11:05 UTC. This page is informational and not investment advice.